Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: Efficacy of hematopoietic stem cell transplantation

Sung Yong Kim, Jennifer Le-Rademacher, Joseph H. Antin, Paolo Anderlini, Mouhab Ayas, Minoo Battiwalla, Jeanette Carreras, Joanne Kurtzberg, Ryotaro Nakamura, Mary Eapen, H. Joachim Deeg

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A proportion of patients with aplastic anemia who are treated with immunosuppressive therapy develop clonal hematologic disorders, including post-aplastic anemia myelodysplastic syndrome. Many will proceed to allogeneic hematopoietic stem cell transplantation. We identified 123 patients with post-aplastic anemia myelodysplastic syndrome who from 1991 through 2011 underwent allogeneic hematopoietic stem cell transplantation, and in a matched-pair analysis compared outcome to that in 393 patients with de novo myelodysplastic syndrome. There was no difference in overall survival. There were no significant differences with regard to 5-year probabilities of relapse, non-relapse mortality, relapse-free survival and overall survival; these were 14%, 40%, 46% and 49% for post-aplastic anemia myelodysplastic syndrome, and 20%, 33%, 47% and 49% for de novo myelodysplastic syndrome, respectively. In multivariate analysis, relapse (hazard ratio 0.71; P=0.18), non-relapse mortality (hazard ratio 1.28; P=0.18), relapse-free survival (hazard ratio 0.97; P=0.80) and overall survival (hazard ratio 1.02; P=0.88) of post-aplastic anemia myelodysplastic syndrome were similar to those of patients with de novo myelodysplastic syndrome. Cytogenetic risk was independently associated with overall survival in both groups. Thus, transplant success in patients with post-aplastic anemia myelodysplastic syndrome was similar to that in patients with de novo myelodysplastic syndrome, and cytogenetics was the only significant prognostic factor for post-aplastic anemia myelodysplastic syndrome patients.

Original languageEnglish (US)
Pages (from-to)1868-1875
Number of pages8
JournalHaematologica
Volume99
Issue number12
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Aplastic Anemia
Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndromes
Immunosuppressive Agents
Survival
Therapeutics
Recurrence
Cytogenetics
Matched-Pair Analysis
Mortality
Multivariate Analysis
Transplants

ASJC Scopus subject areas

  • Hematology

Cite this

Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy : Efficacy of hematopoietic stem cell transplantation. / Kim, Sung Yong; Le-Rademacher, Jennifer; Antin, Joseph H.; Anderlini, Paolo; Ayas, Mouhab; Battiwalla, Minoo; Carreras, Jeanette; Kurtzberg, Joanne; Nakamura, Ryotaro; Eapen, Mary; Deeg, H. Joachim.

In: Haematologica, Vol. 99, No. 12, 01.12.2014, p. 1868-1875.

Research output: Contribution to journalArticle

Kim, SY, Le-Rademacher, J, Antin, JH, Anderlini, P, Ayas, M, Battiwalla, M, Carreras, J, Kurtzberg, J, Nakamura, R, Eapen, M & Deeg, HJ 2014, 'Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: Efficacy of hematopoietic stem cell transplantation', Haematologica, vol. 99, no. 12, pp. 1868-1875. https://doi.org/10.3324/haematol.2014.108977
Kim, Sung Yong ; Le-Rademacher, Jennifer ; Antin, Joseph H. ; Anderlini, Paolo ; Ayas, Mouhab ; Battiwalla, Minoo ; Carreras, Jeanette ; Kurtzberg, Joanne ; Nakamura, Ryotaro ; Eapen, Mary ; Deeg, H. Joachim. / Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy : Efficacy of hematopoietic stem cell transplantation. In: Haematologica. 2014 ; Vol. 99, No. 12. pp. 1868-1875.
@article{507d4543b89d430ca6c248507b2f91c7,
title = "Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: Efficacy of hematopoietic stem cell transplantation",
abstract = "A proportion of patients with aplastic anemia who are treated with immunosuppressive therapy develop clonal hematologic disorders, including post-aplastic anemia myelodysplastic syndrome. Many will proceed to allogeneic hematopoietic stem cell transplantation. We identified 123 patients with post-aplastic anemia myelodysplastic syndrome who from 1991 through 2011 underwent allogeneic hematopoietic stem cell transplantation, and in a matched-pair analysis compared outcome to that in 393 patients with de novo myelodysplastic syndrome. There was no difference in overall survival. There were no significant differences with regard to 5-year probabilities of relapse, non-relapse mortality, relapse-free survival and overall survival; these were 14{\%}, 40{\%}, 46{\%} and 49{\%} for post-aplastic anemia myelodysplastic syndrome, and 20{\%}, 33{\%}, 47{\%} and 49{\%} for de novo myelodysplastic syndrome, respectively. In multivariate analysis, relapse (hazard ratio 0.71; P=0.18), non-relapse mortality (hazard ratio 1.28; P=0.18), relapse-free survival (hazard ratio 0.97; P=0.80) and overall survival (hazard ratio 1.02; P=0.88) of post-aplastic anemia myelodysplastic syndrome were similar to those of patients with de novo myelodysplastic syndrome. Cytogenetic risk was independently associated with overall survival in both groups. Thus, transplant success in patients with post-aplastic anemia myelodysplastic syndrome was similar to that in patients with de novo myelodysplastic syndrome, and cytogenetics was the only significant prognostic factor for post-aplastic anemia myelodysplastic syndrome patients.",
author = "Kim, {Sung Yong} and Jennifer Le-Rademacher and Antin, {Joseph H.} and Paolo Anderlini and Mouhab Ayas and Minoo Battiwalla and Jeanette Carreras and Joanne Kurtzberg and Ryotaro Nakamura and Mary Eapen and Deeg, {H. Joachim}",
year = "2014",
month = "12",
day = "1",
doi = "10.3324/haematol.2014.108977",
language = "English (US)",
volume = "99",
pages = "1868--1875",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "12",

}

TY - JOUR

T1 - Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy

T2 - Efficacy of hematopoietic stem cell transplantation

AU - Kim, Sung Yong

AU - Le-Rademacher, Jennifer

AU - Antin, Joseph H.

AU - Anderlini, Paolo

AU - Ayas, Mouhab

AU - Battiwalla, Minoo

AU - Carreras, Jeanette

AU - Kurtzberg, Joanne

AU - Nakamura, Ryotaro

AU - Eapen, Mary

AU - Deeg, H. Joachim

PY - 2014/12/1

Y1 - 2014/12/1

N2 - A proportion of patients with aplastic anemia who are treated with immunosuppressive therapy develop clonal hematologic disorders, including post-aplastic anemia myelodysplastic syndrome. Many will proceed to allogeneic hematopoietic stem cell transplantation. We identified 123 patients with post-aplastic anemia myelodysplastic syndrome who from 1991 through 2011 underwent allogeneic hematopoietic stem cell transplantation, and in a matched-pair analysis compared outcome to that in 393 patients with de novo myelodysplastic syndrome. There was no difference in overall survival. There were no significant differences with regard to 5-year probabilities of relapse, non-relapse mortality, relapse-free survival and overall survival; these were 14%, 40%, 46% and 49% for post-aplastic anemia myelodysplastic syndrome, and 20%, 33%, 47% and 49% for de novo myelodysplastic syndrome, respectively. In multivariate analysis, relapse (hazard ratio 0.71; P=0.18), non-relapse mortality (hazard ratio 1.28; P=0.18), relapse-free survival (hazard ratio 0.97; P=0.80) and overall survival (hazard ratio 1.02; P=0.88) of post-aplastic anemia myelodysplastic syndrome were similar to those of patients with de novo myelodysplastic syndrome. Cytogenetic risk was independently associated with overall survival in both groups. Thus, transplant success in patients with post-aplastic anemia myelodysplastic syndrome was similar to that in patients with de novo myelodysplastic syndrome, and cytogenetics was the only significant prognostic factor for post-aplastic anemia myelodysplastic syndrome patients.

AB - A proportion of patients with aplastic anemia who are treated with immunosuppressive therapy develop clonal hematologic disorders, including post-aplastic anemia myelodysplastic syndrome. Many will proceed to allogeneic hematopoietic stem cell transplantation. We identified 123 patients with post-aplastic anemia myelodysplastic syndrome who from 1991 through 2011 underwent allogeneic hematopoietic stem cell transplantation, and in a matched-pair analysis compared outcome to that in 393 patients with de novo myelodysplastic syndrome. There was no difference in overall survival. There were no significant differences with regard to 5-year probabilities of relapse, non-relapse mortality, relapse-free survival and overall survival; these were 14%, 40%, 46% and 49% for post-aplastic anemia myelodysplastic syndrome, and 20%, 33%, 47% and 49% for de novo myelodysplastic syndrome, respectively. In multivariate analysis, relapse (hazard ratio 0.71; P=0.18), non-relapse mortality (hazard ratio 1.28; P=0.18), relapse-free survival (hazard ratio 0.97; P=0.80) and overall survival (hazard ratio 1.02; P=0.88) of post-aplastic anemia myelodysplastic syndrome were similar to those of patients with de novo myelodysplastic syndrome. Cytogenetic risk was independently associated with overall survival in both groups. Thus, transplant success in patients with post-aplastic anemia myelodysplastic syndrome was similar to that in patients with de novo myelodysplastic syndrome, and cytogenetics was the only significant prognostic factor for post-aplastic anemia myelodysplastic syndrome patients.

UR - http://www.scopus.com/inward/record.url?scp=84919384670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919384670&partnerID=8YFLogxK

U2 - 10.3324/haematol.2014.108977

DO - 10.3324/haematol.2014.108977

M3 - Article

C2 - 25107891

AN - SCOPUS:84919384670

VL - 99

SP - 1868

EP - 1875

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 12

ER -